A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma

American Journal of Hematology

Volumn 89, Issue 11, 2014, Pages 1037-1042

  Geng, Chuanying ^a   Hou, Jian ^b   Zhao, Yaozhong ^c   Ke, Xiaoyan ^d   Wang, Zhao ^e   Qiu, Lugui ^c   Xi, Hao ^b   Wang, Fuxu ^f   Wei, Na ^e   Liu, Yan ^d   Yang, Shifang ^g   Wei, Peng ^g   Zheng, Xiangjun ^g   Huang, Zhongxia ^a   Zhu, Bing ^g   Chen, Wen Ming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f HEBEI MEDICAL UNIVERSITY   (China)

^g Beijing Sunbio Biotech Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CIRCULARLY PERMUTED TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CREATININE; GLUCOCORTICOID; HEMOGLOBIN; LACTATE DEHYDROGENASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HYPOKALEMIA; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIFE EXPECTANCY; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MALE; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 85007082640     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23822     Document Type: Article

References (24)

1. Chou T. Multiple myeloma: recent progress in diagnosis and treatment. J Clin Exp Hematop 2012;52:149–159.
2. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264–1277.
3. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
4. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–12690.
5. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782–798.
6. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/ TRAIL dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611–620.
7. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010;29:4752–4765.
8. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Gene Dev 2002;16:33–45.
9. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999;13:1817–1824.
10. Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, et al. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007;313:2378–2388.
11. Surget S, Chiron D, Gomez-Bougie P, et al. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012;72:4562–4573.
12. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31–38.
13. Soria JC, Smit E, Khayat D, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010;28:1527–1533.
14. Wiezorek J, Holland P, Graves J. Death Receptor Agonists as a Targeted Therapy for Cancer. Clin Cancer Res 2010;16:1701–1708.
15. Droin N, Guéry L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett 2013;332:325–334.
16. Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Phamacologica Sinica 2005;26:1373–1381.
17. Chen WM, Qiu LG, Hou J, et al. Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients. Blood (ASH Annual Meeting Abstracts) 2012;120:1857.
18. Chen WM, Qiu LG, Hou J, et al. Recombinant circularly permuted TRAIL (CPT) for the treatment of relapsed or refractory multiple myeloma: An open-label, multicenter phase II clinical trial. Blood (ASH Annual Meeting Abstracts) 2012;120:78.
19. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968–3977.
20. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115–1123.
21. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
22. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
23. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772–778.
24. Gores GJ, Kaufmann SH: Is TRAIL hepatotoxic? Hepatology 2001;34:3–6.